ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced the first patient dosed in...
Exact Sciences Corp. (NASDAQ: EXAS) announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer...
Parse Biosciences, a company providing researchers with single-cell sequencing solutions, today announced a partnership with Research Instruments Pte Ltd to provide Parse’s Evercode Whole...
Regeneron Pharmaceuticals, Inc. and Sanofi announced positive pivotal results from a second Phase 3 trial, PRIME, evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo...
